Pharmaceuticals
Docquity and AstraZeneca's Patient Support Program Educates Tens of Thousands in Thailand
* OAZisCare, digitally powered by DocquityCare, has advanced patient education and adherence for cancer care and RSV vaccines since 2024 * The collaboration helps tackle Southeast Asia's healthcare needs, with 85.7% of doctors noting immunization rates could improve with patient support (Do...
2025-04-22 11:00
2426
Everest Medicines Announces Approval of "B" Marker Removal from Company's Stock Code by the Hong Kong Stock Exchange
SHANGHAI, April 22, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that The Stock Exchange of Hong Kong...
2025-04-22 07:45
2069
BGM Group Acquires Wonder Dragon to Accelerate "Healthcare" Strategy
CHENGDU, China, April 21, 2025 /PRNewswire/ -- BGM Group Ltd. (Nasdaq: BGM) today announced that it has signed a definitive transaction agreement with the existing shareholders of Wonder Dragon Global Limited ("Wonder Dragon"), to acquire 100% of the equity interests of Wonder Dragon by issuing 3...
2025-04-21 20:30
3676
Kelun-Biotech's novel ADC drug SKB518 has been granted the clearance of IND from the United States Food and Drug Administration (FDA)
CHENGDU, China, April 21, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company has been granted the clearance of investigational new drug (IND) application to initiated the clinical study of its potential first-in-class innovative ADC ...
2025-04-21 20:10
3817
Acepodia Presents Preclinical Data on Antibody-Dual-Drugs Conjugation (AD2C) technology at AACR Annual Meeting 2025
ALAMEDA, Calif. and TAIPEI, April 21, 2025 /PRNewswire/ -- Acepodia (6976: TT) today announced the presentation of new preclinical data highlighting its proprietary dual-payload antibody-drug conjugate (AD2C) for hepatocellular carcinoma (HCC). The data will be featured at the American Associatio...
2025-04-21 19:00
2081
Rona Therapeutics Announces NMPA Approval of IND Application for RN1871, a Novel Angiotensinogen (AGT)-Targeting siRNA Drug for Hypertension
SHANGHAI, April 21, 2025 /PRNewswire/ -- Rona Therapeutics, a biotechnology company pioneering innovative RNA-targeted therapies, announced that the Investigational New Drug (IND) application for RN1871, a small interfering RNA (siRNA) drug targeting angiotensinogen (AGT), has been approved byChi...
2025-04-21 19:00
3168
DAAN Biotherapeutics and GC Cell Sign Exclusive Technology Transfer Agreement for Tumor Antigen-Specific Antibody Sequence to Advance CAR-T and CAR-NK Cell Therapies
SEOUL, South Korea, April 21, 2025 /PRNewswire/ -- DAAN Biotherapeutics, a leading innovative drug development company specializing in T-Cell receptor (TCR)-based therapies, has signed an exclusive licensing agreement with GC Cell, a gene and cell therapy firm, for the tumor antigen-specific anti...
2025-04-21 15:35
2234
Innovation and Collaboration: Advancing China's Blood Purification Industry
LIUYANG, China, April 19, 2025 /PRNewswire/ -- On April 19, 2025, the Blood Purification Professional Committee (BPPC) of the China Medical Device Industry Association (CMDIA) gathered in Liuyang,Hunan, for its annual conference, themed "Synergy and Endless Innovation." This pivotal event united ...
2025-04-19 14:30
3983
Asieris Pharmaceuticals Releases 2024 Annual Report, with Revenue Exceeding RMB 200M in 1st Year of Commercialization and Innovative Portfolio Accelerating Toward Launch
SHANGHAI, April 18, 2025 /PRNewswire/ -- Asieris Pharmaceuticals today released its 2024 Annual Report, highlighting a bold and determined journey forward. With a specialty pharma strategy and operational efficiency, the company exceeded its commercialization targets and advanced its innovative p...
2025-04-18 22:10
3887
Akeso's Ebdarokimab ( IL - 12/IL - 23 Dual - Targeted Monoclonal Antibody) Approved in China for Moderate - to - Severe Plaque Psoriasis
HONG KONG, April 18, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that ebdarokimab, an investigational monoclonal antibody developed by the company, has received marketing approval from the National Medical Products Administration (NMPA) for the tre...
2025-04-18 19:39
3381
WuXi Biologics Completes First Commercial PPQ Campaign at 15,000L Production Line in Hangzhou Site
- The campaign marks the successful commercial-scale PPQ completion of Asia's first 3 X 5,000L single-use bioreactors - Proprietary process innovation reduces protein cost by nearly 70% while boosting yield 20% - As the company's largest operational single-use bioreactor...
2025-04-18 14:30
4624
Clarity signs high-volume commercial-scale copper-64 Supply Agreement with Nusano
Highlights * Clarity has signed a commercial-scale agreement with Nusano, Inc. ("Nusano") for supply of copper-64 (Cu-64 or64Cu) isotope. * The 190,000 square foot Nusano facility in West Valley City, Utah is capable of producing more than 1,000 Ci (37,000 GBq) of copper-64 per day at capaci...
2025-04-17 21:01
2921
Caliway Selected to Present CBL-514 Phase 2 Study Results for Dercum's Disease at World Orphan Drug Congress USA 2025
* CBL-514, Caliway's novel small molecule drug, was selected for data presentation at the World Orphan Drug CongressUSA 2025, highlighting its promising Phase 2 study results (CBL-0201DD) for Dercum's Disease Treatment. * The Phase 2 topline results met all primary and secondary endpoints, wit...
2025-04-17 18:34
2797
Henlius 2025 Global R&D Day: Harnessing the Power of Innovation to Propel Global Strategy to New Heights
SHANGHAI, April 17, 2025 /PRNewswire/ -- Henlius (2696.HK) held its 2025 Global R&D Day themed "Collaborate to Create," gathering senior executives, experts, and industry leaders to discuss R&D advances, strategic planning, and cutting-edge therapies. The event attracted hundreds from academia, i...
2025-04-17 16:07
4457
Brain Navi Begins IPO Counseling with First Securities Inc., Setting the Stage for Global MedTech Expansion
ZHUBEI, April 17, 2025 /PRNewswire/ -- Brain Navi Biotechnology Co., Ltd. ("
Brain Navi") has officially begun IPO counseling with First Securities Inc.,
marking a strategic step toward accessing the capital markets and advancing its
long-term growth in the surgical robot technology industry.
2025-04-17 12:10
2912
Herbalgy Unveils Touch Cool Campaign at MTR* advertising: An Immersive Installation Fusing Pain Relief with Sustainability and Innovative Design
Download high-resolution images:
2025-04-17 10:00
2670
Norgine welcomes TGA registration in Australia of IFINWIL® (eflornithine) for adults and children diagnosed with high-risk neuroblastoma (HRNB)[1]
* IFINWIL®: now TGA registered in Australia * Children diagnosed with neuroblastoma are on average just 2 years old2 * The average survival rate of children with HRNB is only 50%2 UXBRIDGE, England, April 17, 2025 /PRNewswire/ -- Norgine is pleased to announce that the Australian Therapeutic...
2025-04-17 08:01
2198
Norgine strengthens rare disease portfolio with acquisition of Theravia
Acquisition of Theravia from Mérieux Equity Partners represents meaningful step forward in Norgine's strategy for sustainable growth, adding a complementary portfolio of rare disease medicines Transaction further establishes Norgine's position as a partner of choice for commercialising rare and ...
2025-04-17 08:01
2287
Henlius 2025 Global R&D Day: Harnessing the Power of Innovation to Propel Global Strategy to New Heights
SHANGHAI, April 16, 2025 /PRNewswire/ -- Henlius (2696.HK) held its 2025 Global R&D Day under the theme of "Collaborate to Create". Senior executives from Henlius gathered with leading experts, scholars, and heads of innovation from across the industry to engage in in-depth discussions on the lat...
2025-04-16 23:30
3110
Putting Patients First, Co-Creating a Bright Future for Human Health: Henlius Releases 2024 ESG Report
SHANGHAI, April 16, 2025 /PRNewswire/ -- On April 15, 2025, Henlius (2696.HK) released the "2024 Environmental, Social, and Governance (ESG) Report" (hereinafter referred to as the "ESG Report" or "Report"). This marks the sixth consecutive year that the company has submitted an ESG-related repor...
2025-04-16 23:22
2685
Week's Top Stories
Most Reposted
iQIYI LAND Yangzhou to Open on February 8, Marking New Chapter in China's Immersive Entertainment Scene
[Picked up by 274 media titles]
2026-01-01 10:00
ACEN completes transition to 100% renewable energy
[Picked up by 273 media titles]
2025-12-29 18:53Vietnam's Newest EDM Destination, APLUS SAIGON, Debuts With Star-Studded Soft Opening Weekends Featuring Dombresky and Argy
[Picked up by 273 media titles]
2025-12-30 20:12
CYFIRMA's 2025 Impact Recap Showcases DeCYFIR, Preemptive External Threat Landscape Management Platform, Delivering Measurable Global Defense Against Emerging Threats
[Picked up by 263 media titles]
2025-12-29 09:00
ChinaAMC launches Depository Receipts of two Chinese flagship ETFs in Thai exchange
[Picked up by 260 media titles]
2025-12-29 14:27
